Abstract
Antibody–drug conjugates (ADCs) have transformed targeted cancer therapy, yet treating solid tumors remains challenging due to tumor heterogeneity—where diverse cancer cell subpopulations exhibit variable target expression and differential sensitivity to cytotoxic agents.
To overcome these limitations, next-generation ADC platforms are emerging, including bispecific ADCs and dual-payload ADCs, several of which have already advanced into clinical development. By combining dual targeting with complementary mechanisms of action, dual-payload bispecific ADCs offer a promising strategy to enhance tumor coverage, improve cytotoxic potency, and reduce the risk of therapeutic resistance.
In this webinar, Dr. Haipeng Liu will present Biocytogen’s innovative dual-payload ADC strategy, supported by case studies, and provide a deep dive into its lead dual-payload bispecific ADC—ITGB6×B7H3-vcMMAE-BLD1102—designed to address heterogeneous target expression and variable tumor cell drug sensitivity. Attendees will gain insights into the design principles and translational strategies shaping next-generation dual-payload bispecific ADC development.
Speaker’s Information:
Dr. Haipeng Liu received his Ph.D. in Medicinal Chemistry from Sorbonne University in Paris, where his research focused on supramolecular systems based on cyclodextrins, as well as the development of EGFR-targeted small molecule inhibitors. Prior to that, he earned his master’s degree in Medicinal Chemistry from Tianjin University of Science and Technology, working on influenza virus inhibitor protein conjugates. He also holds a bachelor’s degree in Pharmaceutical Engineering from Inner Mongolia Agricultural University, along with a second major in Business Management. Before joining Biocytogen, Dr. Liu worked as a Product Manager at Jiangsu Hengrui Medicine. Today at Biocytogen, Dr. Liu leads project management efforts in Bispecific ADC development and next-generation antibody-based conjugates.
